WallStreetZenWallStreetZen

NASDAQ: FHTX
Foghorn Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

FHTX past revenue growth

How has FHTX's revenue growth performed historically?
Company
77.63%
Industry
149.51%
Market
17.15%
FHTX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
FHTX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
FHTX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

FHTX earnings and revenue history

Current Revenue
$34.2M
Current Earnings
-$98.4M
Current Profit Margin
-288.2%

FHTX Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%

Be the first to know when FHTX announces earnings.

FHTX Return on Assets

Current Company
-30%
Current Industry
2.9%
FHTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

FHTX Return on Capital Employed

Current Company
-41.41%
Current Industry
19.5%
FHTX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

FHTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
FHTX$34.16M-$85.54M-$98.43M+428.05%N/A
INO$832.01k-$130.39M-$135.12M-51.33%N/A
STRO$153.73M-$66.98M-$106.79M+31.96%N/A
ALDX$0.00-$35.21M-$37.54MN/AN/A
NKTR$90.12M-$243.11M-$276.06M-40.35%N/A
View Top Biotech Stocks

FHTX earnings dates

Next earnings date
May 8, 2024

Foghorn Therapeutics Earnings & Revenue FAQ

What were FHTX's earnings last quarter?

On Invalid Date, Foghorn Therapeutics (NASDAQ: FHTX) reported Q4 2023 earnings per share (EPS) of -$0.57, up 17.39% year over year. Total Foghorn Therapeutics earnings for the quarter were -$24.11 million. In the same quarter last year, Foghorn Therapeutics's earnings per share (EPS) was -$0.69.

If you're new to stock investing, here's how to buy Foghorn Therapeutics stock.

What was FHTX's earnings growth in the past year?

As of Q2 2024, Foghorn Therapeutics's earnings has grown year over year. Foghorn Therapeutics's earnings in the past year totalled -$98.43 million.

What is FHTX's earnings date?

Foghorn Therapeutics's earnings date is Invalid Date. Add FHTX to your watchlist to be reminded of FHTX's next earnings announcement.

What was FHTX's revenue last quarter?

On Invalid Date, Foghorn Therapeutics (NASDAQ: FHTX) reported Q4 2023 revenue of $5.77 million up 37.88% year over year. In the same quarter last year, Foghorn Therapeutics's revenue was $4.18 million.

What was FHTX's revenue growth in the past year?

As of Q2 2024, Foghorn Therapeutics's revenue has grown 77.63% year over year. This is 71.88 percentage points lower than the US Biotechnology industry revenue growth rate of 149.51%. Foghorn Therapeutics's revenue in the past year totalled $34.16 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.